Cognitive impairment and prefrontal TGF-β1 elevation in a rat model of fatigue
-
By
-
Yingru Wu
-
Xuan Wen
-
Zeman Fang
-
Jinling Zhang
-
Handi Zhang
-
June 19, 2026
-
Clinical Scorecard: Elevated Prefrontal TGF-β1 and Cognitive Dysfunction Observed in a Rat Model of Chronic Fatigue
At a Glance
| Category | Detail |
|---|
| Condition | Chronic Fatigue Syndrome (CFS) |
| Key Mechanisms | Dysregulated cytokines, particularly TGF-β1, implicated in cognitive dysfunction. |
| Target Population | Individuals with Chronic Fatigue Syndrome. |
| Care Setting | Preclinical research using a rat model. |
Key Highlights
- CFS characterized by persistent fatigue and cognitive dysfunction.
- Elevated prefrontal TGF-β1 levels observed in fatigued rats.
- Fatigue model induced cognitive impairment and increased anxiety-like behavior.
- Behavioral tests included open field and Y-maze tests.
- Cytokine imbalance, particularly TGF-β1, may play a role in CFS pathophysiology.
Guideline-Based Recommendations
Diagnosis
- CFS diagnosis based on persistent fatigue lasting more than six months.
Management
- Further investigation into cytokine profiles and their implications for treatment.
Monitoring & Follow-up
- Monitor cognitive and emotional functions in patients with CFS.
Risks
- Prolonged fatigue can lead to decline in social functioning and quality of life.
Patient & Prescribing Data
Individuals diagnosed with Chronic Fatigue Syndrome.
Potential role of TGF-β1 as a biomarker for CFS management.
Clinical Best Practices
- Utilize behavioral assessments to evaluate cognitive function in CFS.
- Consider cytokine profiling in the evaluation of CFS patients.
Related Resources & Content
